AR001036A1 - Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento - Google Patents

Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento

Info

Publication number
AR001036A1
AR001036A1 ARP960101524A AR10152496A AR001036A1 AR 001036 A1 AR001036 A1 AR 001036A1 AR P960101524 A ARP960101524 A AR P960101524A AR 10152496 A AR10152496 A AR 10152496A AR 001036 A1 AR001036 A1 AR 001036A1
Authority
AR
Argentina
Prior art keywords
procedure
compounds
phenylnaphyllum
exclusive application
prepare
Prior art date
Application number
ARP960101524A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR001036A1 publication Critical patent/AR001036A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/295—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ARP960101524A 1995-02-28 1996-02-26 Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento AR001036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/395,950 US5998401A (en) 1995-02-28 1995-02-28 Naphthyl compounds, intermediates, compositions, and methods

Publications (1)

Publication Number Publication Date
AR001036A1 true AR001036A1 (es) 1997-08-27

Family

ID=23565221

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP960101524A AR001036A1 (es) 1995-02-28 1996-02-26 Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento
ARP960101525A AR002964A1 (es) 1995-02-28 1996-02-26 Compuestos de 1(4-hidroxifenil)-2-fenoxi-naftilo, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y compuestosintermediarios de aplicacion en dicho procedimiento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP960101525A AR002964A1 (es) 1995-02-28 1996-02-26 Compuestos de 1(4-hidroxifenil)-2-fenoxi-naftilo, procedimiento para prepararlos, composiciones farmaceuticas que los contienen y compuestosintermediarios de aplicacion en dicho procedimiento.

Country Status (32)

Country Link
US (5) US5998401A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0729951B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH08268881A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR960030938A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN1053886C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR001036A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE180776T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU694837B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9600821A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2170337A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO4700421A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2178B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ288213B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69602638T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0729951T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2132841T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI115524B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3030407T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL117168A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN182138B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9600743A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY113232A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO305833B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ286072A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE28497A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL183578B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2167849C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG55098A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR199600126A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW349946B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU11496A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA961291B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5856339A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
EP1142862A3 (en) * 1996-08-29 2002-10-02 Eli Lilly And Company Naphthyl and tetralone derivatives as intermediates
CA2213814A1 (en) * 1996-08-29 1998-02-28 Henry Uhlman Bryant Naphthalene compounds, intermediates, formulations, and methods
CA2214929A1 (en) * 1996-09-26 1998-03-26 Charles Willis Lugar, Iii Naphthofluorene compounds, intermediates, compositions and methods
CA2214931A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Tetrahydrobenzo-a-fluorene compounds and method of use
CA2214935A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Benzofluorene compounds, intermediates, compositions, and methods
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
IT1298159B1 (it) * 1997-01-28 1999-12-20 Hoffmann La Roche Derivati di un 5-aroilnaftalene
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
ES2239793T3 (es) 1997-08-07 2005-10-01 Eli Lilly And Company Compuestos de 1-(4-(alcoxi sustituido)bencil)naftaleno con actividad inhibidora de estrogenos.
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
IL145839A0 (en) 1999-04-16 2002-07-25 Astrazeneca Ab ESTROGEN RECEPTOR-β LIGANDS
US6312474B1 (en) * 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
KR100370597B1 (ko) * 2000-06-22 2003-02-05 박정일 산형매립초로부터 분리한 신규한 나프탈렌계 화합물 및이를 유효성분으로 하는 약학적 조성물
US7045628B2 (en) * 2000-11-28 2006-05-16 Eli Lilly And Company Synthesis of 2-aryl-1-naphthol derivatives via a tandem palladium catalyzed arylation and dehydrogenation
ES2236536T3 (es) * 2001-05-22 2005-07-16 Eli Lilly And Company Derivados tetrahidroquinolino para la inhibicion de enfermedades asociadas con la privacion de estrogenos o con una respuesta fisiologica aberrante a estrogenos endogenos.
ATE321754T1 (de) 2001-05-22 2006-04-15 Lilly Co Eli 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren
US6914074B2 (en) 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
CA2490580C (en) 2002-07-22 2012-12-11 Eli Lilly And Company Selective estrogen receptor modulators containing a naphthalene group
US9315539B2 (en) * 2002-10-01 2016-04-19 Yale University 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer
WO2004075894A1 (en) 2003-02-25 2004-09-10 Eli Lilly And Company Crystalline non-solvated 1-(4-(2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride
EA007978B1 (ru) * 2003-02-25 2007-02-27 Эли Лилли Энд Компани Кристаллический несольватированный гидрохлорид 1-(4-(2-пиперидинилэтокси)фенокси)-2-(4-метансульфонилфенил)-6-гидроксинафталина
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
JP4589337B2 (ja) * 2003-11-20 2010-12-01 イーライ リリー アンド カンパニー ビタミン受容体調節剤
WO2005051898A2 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
CN102250042A (zh) 2004-01-22 2011-11-23 伊莱利利公司 用于治疗血管舒缩症状的选择性雌激素受体调节剂
EP1709023B1 (en) 2004-01-22 2009-11-11 Eli Lilly And Company Selective estrogen receptor modulators
CN1910167B (zh) * 2004-01-22 2011-08-10 伊莱利利公司 用于治疗血管舒缩症状的选择性雌激素受体调节剂
KR20070026841A (ko) * 2004-06-22 2007-03-08 스미스클라인 비참 코포레이션 화합물
TWI396543B (zh) * 2005-05-12 2013-05-21 Sankyo Co 取代丙烯醯胺衍生物及含有它之醫藥組成物
EA020742B1 (ru) * 2008-09-29 2015-01-30 Эли Лилли Энд Компани Селективный модулятор рецепторов эстрогена
KR20150039882A (ko) 2010-06-16 2015-04-13 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
EP3390364B1 (en) 2015-12-17 2020-07-15 Biokine Therapeutics Ltd. Small molecules for inhibiting chemokine activity and/or cancer cells growth
CN114096524B (zh) 2019-05-15 2025-03-04 阿龙拜欧有限公司 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3396169A (en) * 1966-10-26 1968-08-06 Upjohn Co Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3313853A (en) * 1963-10-16 1967-04-11 Upjohn Co 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones
US3293263A (en) * 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3320271A (en) * 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
GB1138163A (en) * 1965-05-21 1968-12-27 Bristol Myers Co Benzothiophene derivatives having anti-fertility properties
US3394125A (en) * 1965-10-23 1968-07-23 Bristol Myers Co 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group
US3483293A (en) * 1967-12-15 1969-12-09 Upjohn Co Method for controlling birds and rodents
US3567737A (en) * 1968-01-02 1971-03-02 Upjohn Co Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes
US3862323A (en) 1971-09-20 1975-01-21 Betz Laboratories Dioxide slime control composition and its use
US4400543A (en) * 1975-10-28 1983-08-23 Eli Lilly And Company 3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
GB8705174D0 (en) * 1987-03-05 1987-04-08 Ici Plc Heterocyclic compounds
US5017572A (en) * 1988-04-22 1991-05-21 Delalande S.A. Derivatives of 1-[3-(4-hydroxyphenyl) 1-hydroxy 1-propyl] benzene substituted in position 2 by an aminoalkyleneoxy chain, the method of preparing same and the application thereof to therapeutics
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
CA1333905C (en) * 1988-10-21 1995-01-10 Swati Bal-Tembe Branched-chain alkyl esters of 2-[4-(2-piperidino-ethoxy) -benzoyl]-benzoic acid, processes for their preparation and their use as spasmolytic agents
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
DE4117512A1 (de) 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
NZ245260A (en) * 1991-11-27 1995-06-27 Novo Nordisk As Piperidine derivatives, preparation and pharmaceutical compositions thereof
US5424334A (en) 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
WO1994014786A1 (en) * 1992-12-22 1994-07-07 Smithkline Beecham Plc Piperidine derivatives as calcium channel antagonists
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Also Published As

Publication number Publication date
US5574190A (en) 1996-11-12
ZA961291B (en) 1997-08-19
CN1053886C (zh) 2000-06-28
CN1137525A (zh) 1996-12-11
EP0729951A1 (en) 1996-09-04
GR3030407T3 (en) 1999-09-30
KR960030938A (ko) 1996-09-17
CZ288213B6 (en) 2001-05-16
NO960772L (no) 1996-08-29
PE28497A1 (es) 1997-08-27
NO960772D0 (no) 1996-02-26
RU2167849C2 (ru) 2001-05-27
IL117168A (en) 2001-11-25
TR199600126A1 (tr) 1996-10-21
AU4573296A (en) 1996-09-05
IL117168A0 (en) 1996-06-18
FI115524B (fi) 2005-05-31
US5998401A (en) 1999-12-07
PL183578B1 (pl) 2002-06-28
NO305833B1 (no) 1999-08-02
US6268361B1 (en) 2001-07-31
EP0729951B1 (en) 1999-06-02
ES2132841T3 (es) 1999-08-16
FI960889A0 (fi) 1996-02-26
CN1152683C (zh) 2004-06-09
AR002964A1 (es) 1998-05-27
MY113232A (en) 2001-12-31
CY2178B1 (en) 2002-08-23
JPH08268881A (ja) 1996-10-15
CZ58196A3 (en) 1996-09-11
AU694837B2 (en) 1998-07-30
DK0729951T3 (da) 1999-06-23
TW349946B (en) 1999-01-11
US6355632B1 (en) 2002-03-12
DE69602638D1 (de) 1999-07-08
NZ286072A (en) 1996-10-28
FI960889A7 (fi) 1996-08-29
MX9600743A (es) 1997-02-28
CN1261534A (zh) 2000-08-02
IN182138B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1999-01-09
US5567712A (en) 1996-10-22
CO4700421A1 (es) 1998-12-29
SG55098A1 (en) 1998-12-21
CA2170337A1 (en) 1996-08-29
BR9600821A (pt) 1997-12-23
ATE180776T1 (de) 1999-06-15
PL312829A1 (en) 1996-09-02
YU11496A (sh) 1999-03-04
DE69602638T2 (de) 1999-10-21

Similar Documents

Publication Publication Date Title
AR001036A1 (es) Procedimiento para preparar compuestos de fenoxi -2- fenilnaftilo y compuestos intermediarios de aplicacion exclusiva en dicho procedimiento
PT96897A (pt) Processo para a preparacao de novos compostos aril-e heteroariletilenicos e de composicoes farmaceuticas que os contem
ES2083438T3 (es) Procedimiento para la preparacion de taxol utilizando una oxazinona.
BR9916772A (pt) Quinolinacarboxamidas como agentes antivirais
TW336939B (en) Lipopeptide derivatives, a process for their preparation and their use
CO5210864A1 (es) Nuevos derivados de bencimidazolonas que tienen afinidad para receptores mezclados de serotonina y dopamina
KR910015568A (ko) 신경 보호성 3-피페리디노-4-하이드록시 크로만 유도체
ES2155566T3 (es) Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia.
BR9808486A (pt) Processo para a preparação de um composto
ES488788A0 (es) Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa.
KR950004377A (ko) 안트라센 유도체
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
KR920002151A (ko) 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
CO4700291A1 (es) Compuestos quimicos
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
AR004691A1 (es) Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion
ES2185967T3 (es) Procedimiento para preparar derivados acidos beta-amino-alfa-hidroxi.
CO5011066A1 (es) Compuestos de triazina
BR9911250A (pt) Processo para preparação de compostos
FI892991A0 (fi) Nya 4,5,7,8-tetrahydro-6h-tiazolo/5,4-d /azepiner, deras framstaellning och deras anvaendning som laekemedel.
KR950700233A (ko) 아미노산 유도체 및 항활성산소제(Amino acid derivatives and anti-active oxygen agents)
ES527318A0 (es) Un procedimiento para la preparacion de derivados de fenilpiperazina
SE9002596D0 (sv) A method for synthesis of prostaglandin derivatives
ES2172768T3 (es) Procedimiento para preparar un compuesto de fosfito multidentado.
KR910009271A (ko) 15-케토-프로스타글란딘 화합물을 이용한 폐 부전증의 치료

Legal Events

Date Code Title Description
FG Grant, registration